Literature DB >> 34857388

Inflammatory breast cancer, trimodal treatment, and mortality: Does where you live matter?

Theresa Relation1, Yaming Li2, James L Fisher3, Allan Tsung2, Bridget Oppong2, Mariam F Eskander2, Samilia Obeng-Gyasi4.   

Abstract

BACKGROUND: The objective of this study is to examine the associations among neighborhood socioeconomic status, trimodal treatment, and disease-specific mortality among inflammatory breast cancer patients using data from the Surveillance, Epidemiology, and End Results program.
METHODS: Patients diagnosed with inflammatory breast cancer (T4d) from 2010 to 2016 were identified in the Surveillance, Epidemiology, and End Results program. The cohort was stratified into neighborhood socioeconomic status groups (low, middle, high) based on National Cancer Institute census tract-level index. Trimodal treatment was defined as receipt of modified radical mastectomy, chemotherapy, and radiation therapy. Bivariable analysis, log-rank test, and a Cox proportional hazards model (hazard ratio, 95% confidence interval) were conducted to evaluate the relationship between neighborhood socioeconomic status, trimodal treatment, and disease-specific mortality.
RESULTS: In total, 4,374 patients met study criteria. There was no difference between the neighborhood socioeconomic status groups in receipt of trimodal treatment (P = .19). On multivariable analysis, there was no association between low neighborhood socioeconomic status (hazard ratio 1.13, 0.98-1.30; ref high neighborhood socioeconomic status) or middle neighborhood socioeconomic status (hazard ratio 1.01, 0.88-1.64; ref high neighborhood socioeconomic status) and disease-specific mortality. Notably, triple negative subtype (hazard ratio 2.66, 2.21-3.20; ref luminal A) and Black race (hazard ratio 1.41, 1.16-1.72; ref White) were associated with a higher disease-specific mortality.
CONCLUSION: For inflammatory breast cancer patients in the Surveillance, Epidemiology, and End Results program, disease-specific mortality appears to be driven by tumor biology and patient characteristics instead of treatment disparities or neighborhood socioeconomic status.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34857388      PMCID: PMC8885962          DOI: 10.1016/j.surg.2021.08.061

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  22 in total

1.  Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver
Journal:  Breast Cancer Res Treat       Date:  2012-06-26       Impact factor: 4.872

2.  Impact of NCI Socioeconomic Index on the Outcomes of Nonmetastatic Breast Cancer Patients: Analysis of SEER Census Tract-Level Socioeconomic Database.

Authors:  Omar Abdel-Rahman
Journal:  Clin Breast Cancer       Date:  2019-08-21       Impact factor: 3.225

3.  The implications of insurance status on presentation, surgical management, and mortality among nonmetastatic breast cancer patients in Indiana.

Authors:  Samilia Obeng-Gyasi; Lava Timsina; Kathy D Miller; Kandice K Ludwig; Carla S Fisher; David A Haggstrom
Journal:  Surgery       Date:  2018-08-28       Impact factor: 3.982

4.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

5.  Comparing national cancer registries: The National Cancer Data Base (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program.

Authors:  Sanjay Mohanty; Karl Y Bilimoria
Journal:  J Surg Oncol       Date:  2014-01-25       Impact factor: 3.454

Review 6.  Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer.

Authors:  Arjun Menta; Tamer M Fouad; Anthony Lucci; Huong Le-Petross; Michael C Stauder; Wendy A Woodward; Naoto T Ueno; Bora Lim
Journal:  Surg Clin North Am       Date:  2018-05-24       Impact factor: 2.741

7.  Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study.

Authors:  San-Gang Wu; Wen-Wen Zhang; Jun Wang; Yong Dong; Jia-Yuan Sun; Yong-Xiong Chen; Zhen-Yu He
Journal:  Future Oncol       Date:  2018-10-31       Impact factor: 3.404

8.  A comprehensive evaluation of outcomes for inflammatory breast cancer.

Authors:  Relin Yang; Michael C Cheung; Judith Hurley; Margaret M Byrne; Youjie Huang; Teresa A Zimmers; Leonidas G Koniaris
Journal:  Breast Cancer Res Treat       Date:  2009-01-24       Impact factor: 4.872

Review 9.  User's guide to correlation coefficients.

Authors:  Haldun Akoglu
Journal:  Turk J Emerg Med       Date:  2018-08-07

10.  International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Authors:  Naoto T Ueno; Jose Rodrigo Espinosa Fernandez; Massimo Cristofanilli; Beth Overmoyer; Dan Rea; Fedor Berdichevski; Mohamad El-Shinawi; Jennifer Bellon; Huong T Le-Petross; Anthony Lucci; Gildy Babiera; Sarah M DeSnyder; Mediget Teshome; Edward Chang; Bora Lim; Savitri Krishnamurthy; Michael C Stauder; Simrit Parmar; Mona M Mohamed; Angela Alexander; Vicente Valero; Wendy A Woodward
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.